Clinical Trials

Leading the treatment of adenoviral conjunctivitis

Doctors in Australia are currently conducting the RUBY Trial.

The study will evaluate OKG-0301 eye drops, to evaluate the reduction of the signs and symptoms of adenoviral conjunctivitis, as well as the overall length of infection.

Results from our RUBY Trial demonstrate that OKG-0301 is a safe, effective and dose-responsive anti-viral medication.

OKG-0301 is a safe and effective antiviral

  • qPCR & CC-IFA demonstrate consistent, dose-responsive antiviral activity
  • AE profile (ocular & non-ocular) is uneventful
  • Ph2b planned with OKG-0502 (RUBY II)
More information about clinical trial results can be found at clinicaltrials.gov
Learn More About the RUBY Trial

Latest News & Press

View All News
Press Release

Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer

March 8, 2022
Read More
Press Release

Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis–Phase 2 Interim Analysis Results from RUBY Clinical Trial

April 29, 2021
Read More
Press Release

Okogen Initiates Phase 2 Clinical Trial (RUBY) of OKG-0301 in Patients

January 31, 2019
Read More

© 2021 Okogen, Inc. All Rights Reserved

United States

Okogen, Inc.
332 Encinitas Blvd. Suite 102
Encinitas, CA 92024, USA

Australia

Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000 AUS

Main Menu